Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Total Liabilities (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Total Liabilities for 5 consecutive years, with $50.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 1.27% to $50.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $50.0 million, a 1.27% decrease, with the full-year FY2024 number at $53.5 million, down 15.63% from a year prior.
  • Total Liabilities was $50.0 million for Q3 2025 at Werewolf Therapeutics, down from $51.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $74.0 million in Q1 2023 to a low of $7.1 million in Q1 2021.
  • A 5-year average of $43.9 million and a median of $49.9 million in 2025 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: soared 413.29% in 2022, then fell 25.44% in 2024.
  • Werewolf Therapeutics' Total Liabilities stood at $26.5 million in 2021, then surged by 43.25% to $37.9 million in 2022, then surged by 67.4% to $63.5 million in 2023, then fell by 15.63% to $53.5 million in 2024, then decreased by 6.59% to $50.0 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Total Liabilities are $50.0 million (Q3 2025), $51.1 million (Q2 2025), and $49.9 million (Q1 2025).